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What Already Known About This Subject 
 
•  There have been numerous ethical, scientific and pragmatic barriers to the conduct of early 
Phase drug studies in children. 
•  This has resulted in a therapeutic gap in that drugs are frequently used in children on an 
“off label” basis which has been associated with an increased risk for adverse effects. 
 
What This Review Adds  
 
•  There have been a number of developments in the past decade that have addressed the 
ethical and feasibility barriers to conduct of drug studies in children.  
•  This review provides a perspective on these developments as well as the regulatory changes 
mandating studies in children for new therapeutic agents in Europe and the US. 
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Summary 
 
It has historically very difficult to conduct early Phase drug studies in children for a number 
of reasons related to ethics, acceptability, rarity, standardization, end points, safety, dosing 
and feasibility.  Over the past decade there have been a number of developments including 
novel clinical trial design, in silico pharmacology and microdosing that have significantly 
enhanced the ability of investigators to conduct early phase drug studies in children.  While 
the evolution of drug therapy is creating a series of new challenges, there has never been a 





The current drug development process began after the Elixir of Sulfanilamide tragedy – in 
which a number of children died due to the use of diethylene glycol as a solvent - triggered 
the passage of the US Food and Drug Act in 1938 (1).  This was intended to ensure that drugs 
were safe and effective prior to approval for marketing.  It should not be forgotten that the 
impetus for this act was a therapeutic disaster largely involving children.   One consequence 
of this was the current drug development process, which after pre-clinical studies involves 
Phase I (first-in-man), Phase II (first-in-patient) and Phase III (comparison to standard 
therapy) studies.  An additional tragedy that spurred changes in drug regulation was the 
Thalidomide Tragedy in the early 1960’s that led to both the Kefauver-Harris amendments to 
the Food and Drug Act in 1962 and the creation of national spontaneous reporting schemes 
for adverse drug reactions such as the Yellow Card Scheme in the UK (2, 3).  While children 
have benefitted from the spontaneous reporting schemes, the other changes that were 
intended to provide safer drug therapy for children had quite the opposite effect.  The 
Kefauver-Harris amendments stated in order to be approved for marketing a drug must not 
only be safe but also have substantial evidence of benefit under the conditions of use as 
defined in the product monograph, and provided powers for the Food and Drug 
Administration to enforce this. The result was that, rather than ensuring that well designed 
studies were conducted in children, product monographs simply stated, in more or less 
similar terms, that safety and efficacy of the drug in question had not been evaluated in 
children along with a legal disclaimer against use in children (2).  This unintended 
consequence of a well meaning act was best described by Shirkey who used the term “the 
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therapeutic orphan” to describe that the majority of drugs on the market had no labeling for 
use in children – despite the fact that these drugs were commonly used, often as first line 
therapy, in children (2,4).   
 
Over the past 20 years there has been a concerted effort to address these problems, including 
development of national and international research networks to conduct drug research in 
children as well as changes in the drug approval process by drug regulatory authorities that 
have not only increased knowledge with respect to approved drugs but also have mandated 
inclusion of children in pre-marketing studies of drugs likely to be used by children (5).  
Examples include the Best Pharmaceuticals for Children Act and the Pediatric Research 
Equity Act that became a permanent part of American law as part of the Congressional 
approval of the FDA Safety and Innovation Act in 2012 and the European equivalent, the 
Regulation on Medicines for Paediatric Use (5,6)  The regulatory agencies on both sides of 
the Atlantic have the ability – and indeed the mandate – to require companies making new 
drug submissions to provide a detailed plan (Pediatric Study Plan in USA, Paediatric 
Investigation Plan in Europe) for drugs likely to be used in children. New therapies that are 
likely to be useful in treatment of children will therefore need to include children as part of 
their drug development plans (7,8).  This will create challenges as this has historically not 
been part of drug development planning for most new therapeutic entities, but there are also a 
number of advances that present opportunities to address this. 
 
The conduct of early phase drug research is challenging at the best of times (9).  There are a 
number of specific issues associated germane to enrollment of children in early phase drug 




The involvement of children in research studies has been hotly debated and this is a field in 
constant flux.  Since the “Great Divide” after World War II that established the importance of 
research ethics and informed consent, there as been an on-going debate as to the ethical issues 
involved in the participation of children in research (9-11).   This has been true in the United 
States, Europe (ftp://ftp.cordis.europa.eu/pub/fp7/docs/ethical-considerations-
paediatrics_en.pdf), Canada (http://www.pre.ethics.gc.ca/eng/policy-
politique/initiatives/tcps2-eptc2/Default/) and many other jurisdictions (12).  Historically 
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there has been a pendulum varying between a somewhat lassie faire approach to inclusion of 
children in drug studies with the arguably nihilistic view that children should not be involved 
in drug studies (9-12).  Over the past decade the position has increasingly been made that 
drug studies in children are essential in order to provide evidence to guide safe and effective 
drug therapy and to facilitate the development of drugs for common and important paediatric 
disorders (13).   
 
There are now ethical constructs that permit and even encourage involvement of children in 
drug research, notably when this will be of material benefit to children with disorders 
targeted by the agent in question.  There is on-going discourse and evolution that increasingly 
this has included discussion of ensuring that being involved in research would not involve 
more than minimal risk.  While avoiding minimal risk usually means that with the exception 
of children with cancer it is unlikely children will be involved in Phase I studies children 
would certainly be ethically eligible for Phase II and Phase III studies.  There has been an 
increasingly call that ethical approval would require not only consent from parents but also 
assent from the children, certainly for adolescents (14-16).  The question of how best to 
secure informed consent for drug research in adolescents remains problematic, in that in 
many jurisdictions informed minors can consent to significant medical procedures – 
including those associated with significant risk – but often cannot themselves consent for 
participation even in very low risk research studies.  This remains an area of active debate 




The issue of acceptability alludes to questions with the child’s family and also with 
clinicians, institutions and investigators.  Historically there has been believed to be reluctance 
for parents to enroll children in clinical trials.  Recent work has suggested that this may be 
more perception than reality (17-19).  A multi-centre study in France demonstrated that 
refusal rate for clinical studies in children was related to the perceived burden on the family 
on the part of the paediatrician charged with enrolling patients in the study (20).   This 
supports our finding in an earlier Anglo-Canadian study that showed that paediatricians with 
limited training in ethics were very reluctant to enroll children in clinical trials (19).  The 
degree of comfort of study personnel in working with children and families appears to be a 
key factor in success or failure of drug studies in children with respect to enrollment or lack 
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thereof.  It is also increasingly evident that children are interested in being involved in studies 
for altruistic reasons with respect to the well being of other children.   
 
In addition to individual investigators the degree of comfort with drug studies in children 
varies considerably between institutions, sometimes with no clear link between experience in 
child health care and degree of comfort for recruiting children to drug studies.  In this 
context, the creation of regional and national networks for children’s research has been a 
great opportunity in terms of providing standards and resources to enhance the design and 
conduct of clinical research – including drug research – in children.  An early example was 
the National Institutes of Health Pediatric Pharmacology Research Network linking research 
units throughout the United States while a more recent example germane to the UK is the 
Medicines for Children Research Network created by the National Health Service which 
brought together expertise in paediatric drug studies across the United Kingdom (22).  In the 
latter case this has been merged with the Paediatric Specialty Group to create a community of 
clinical practice that provides national research expertise in studies involving children, 
including drug studies (https://www.crn.nihr.ac.uk/children/).  This creates the opportunity 




The issue of rarity speaks to a dichotomous reality in paediatric health care, in that many 
disorders are rare at any individual institution but are collectively reasonably common. We 
demonstrated this in a study of drug utilization in a cohort of one million Canadian children 
followed for a year, in which 70% of drug use was among 20% of children, these children 
representing a number of serious and chronic conditions (23).  We also found that these 
children were largely cared for in 16 academic health science centres across the country.  
Hence clinical trials of new therapies are clearly needed but it is difficult to use a single 
centre and sample size was been a frequently cited problem for drug studies in children (6). 
 
Thus in addition to acceptance the development of regional, national and international 
networks have been instrumental in providing mechanisms for timely recruitment of large 
numbers of patients using common instruments and with the evaluation of common 
outcomes.  This has been most successful in paediatric Haematology-Oncology and 
Neonatology, as both fields have made considerable progress in assessing therapy and 
  
This article is protected by copyright. All rights reserved. 
developing evidence-based treatment protocols which have resulted in the survival of very 
small pre-term infants and a very high rate of cure for many childhood cancers (6, 24, 25).  
Increasingly other groups – including academic general paediatricians and critical care 
paediatricians – are developing networks to apply the strength of synergy to problems within 
their care and research domains (26, 27).  The existence and development of these networks 
provides a much improved platform to support drug research in children.  Additionally, these 
networks can support highly specialized units such as Phase I units for childhood cancer, 
facilities that are uncommon but very important (28. 29).      
 
Standardization, End Points and Safety 
 
One of the key elements in drug research is the clinical trial.  Since the first curative clinical 
trial - conducted in 1946-47 by the MRC Tuberculosis Research Unit to study streptomycin 
in the management of pulmonary tuberculosis – the randomized clinical trial has become a 
gold standard in the drug development process (6, 30, 31).  For many years a randomized 
placebo-controlled double blind clinical trial was considered essential to the drug 
development and approval process.  This has been a problem in drug studies in children for 
several reasons (6).  There have been issues with ethical approval and conduct as noted 
above.  As well, there has been reluctance to use placebos during drug research in children.  
As the number of effective therapies has evolved, this question has become germane as well 
to clinical trials involving adults. 
 
A key question is selection of a suitable end point, notably as this drives sample size and 
analysis strategy (6, 32).  These end points may include biomarkers, the validity of which 
may have not been established in children. Development of valid and reproducible end points 
has become a research field in and of itself.  An issue that complicates clinical trials in 
children is that many end points that are commonly used in adult clinical trials have not been 
validated in children – or indeed may not be possible (6).  As an example, the evaluation of 
the efficacy of analgesic interventions in young children and infants was problematic as many 
validated instruments for the evaluation of pain involved self-report, a problem for 
populations that are non-verbal or who lack numerical literacy (33).  However, great progress 
has been made over the past two decades in developing and validating end points that are 
relevant to and achievable in studies involving children.  To return to the issue noted above, 
there have been a number of scales and observation tools developed that provide investigators 
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with valid tools to study the effect of various interventions on pain on even the youngest of 
infants (33, 34).      
 
In addition to progress in the selection of end-points there have been a number of advances in 
the design of clinical trials for children.  Analysis of clinical trials conducted in children has 
suggested that many designs used to date are associated with a significant risk of bias, 
notably with respect to sequence generation and allocation concealment (35).  As well, the 
perception of lack of flexibility has historically a problem for randomized drug studies in 
children (36).   Over the past decade a number of novel trial designs have been developed to 
address these issues.  One example is sequential design in which investigators conduct 
frequent analysis during subject enrollment to determine if the therapy of interest is superior 
(37).  A type of sequential design suggested to be very useful for studies in children is 
adaptive design, in which planned interim analysis is used to inform modifications in trial 
design (38).  This type of trial requires meticulous pre-trial planning and consideration for 
issues such as blinded versus non-blinded interim analysis (39).  This can permit a trial to be 
stopped early in the case of an intervention that is either very effective or found to be 
ineffective, reducing the number of children needed for the trial.  These trial designs may be 
unfamiliar to drug regulatory agencies and investigators planning on using them for early 
phase drugs studies are encouraged to discuss this with their respective drug regulatory 
agency.     
 
An additional issue of key importance in any clinical trial and most certainly those involving 
drugs is a robust and on-going safety assessment (40).  The drug approval process was 
designed to detect serious and common risks, and while this is generally the case it is clear 
from events such as the unfortunate events associated with the initial clinical trials of 
TGN1412 in the UK and fatty acid amide hydrolase (FAAH) inhibitors in France that serious, 
even fatal, adverse effects still occur (41).  This is of particular importance in the drug 
evaluation process for children as some common and important adverse drug effects are 
different in both incidence and manifestation in children than in adults (42, 43).  The increase 
in interest in drug therapy for children over the past two decades has been accompanied by 
the development of new instruments both clinically and in vitro that offer considerable 
promise for more rapid and focused detection of adverse drug events in children, notably for 
novel therapeutic agents (44, 45).   
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An emerging area in clinical trial design with special relevance to children is the use of 
simulation and modeling early in the drug development process (46, 47).  The value that 
simulation and modeling brings is the ability to factor in variables such as ontogeny of key 
pathways of drug clearance and data derived from adult studies to develop estimates for drug 
dosing which enables a clearer estimate of dose while reducing the requirement for additional 
studies (47).  As well, simulation can be used to provide firmer estimates of sample size and 
to illustrate the point at which increasing sample size does not significantly increase the 
precision of data gathered (47).  The increasing sophistication of pharmacometrics in children 
also provides new opportunities. 
 
Dosing and Feasibility 
 
There are feasibility issues with respect to involvement of children in early phase drug studies 
and first among them is dose selection.  The issue of dose selection for Phase I trials is 
problematic at the best of times and the increasing percentage of biological as new 
therapeutic entities has only increased this problem.  A recent review of failed paediatric drug 
development trials has suggested that in up to a quarter of trials that fail to establish efficacy 
or safety the selection of the correct dose was a factor in this failure (48).   
 
The conventional approach to developing dose considerations for children has been to 
extrapolate from adult dosing, often using techniques such as allometric scaling. This may be 
problematic in that the major issues in ontogeny directly impact on drug clearance, primarily 
in terms of a reduction in the capacity of children to clear drugs or drug metabolites, notably 
in infancy (49).  While this is now well understood for drugs used in the first year of life, an 
under-appreciated issue is that toddlers are notably more efficient in terms of oxidative 
metabolism, which may increase the risk for toxicity in drugs that undergo biotransformation 
to active metabolites (50).   
 
Better appreciation of the role of ontogeny and disease enables a more rationale of drug 
dosing for paediatric studies (51).  A technique with considerable potential is microdosing in 
which a pharmacokinetic study is done using a subtherapeutic dose of a 
14
C labeled drug (52-
54).  This can be done as a “Phase 0” study prior to a Phase 1 or Phase 2 trial.   Advances in 
analytical technology have been such that concerns about the volume of blood needed for 
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pharmacokinetic studies – once a major concern in paediatrics – is now largely a historical 
curiosity except for very premature infants. 
 
Once a dose has been selected a consideration somewhat unique to paediatric drug studies is 
formulation.  While drugs for adults – notably chronic therapy – are overwhelmingly given 
orally as tablets or capsules, the use of drugs in children must take into account the fact that 
medication naïve children under the age of 8 find it difficult to take tablets or capsules and 
even medication sophisticated children cannot reliably take medication in conventional 
tablets or capsules.  The traditional approach to this problem has been to develop liquid 
formulations or crush the tablets (55).  Over the past decade there has been an explosion in 
the creation of novel dosing systems designed for children, work largely driven by 
developments in Europe and which offers great promise for making drug research – and drug 




While there have been many cultural, scientific and regulatory challenges that have made 
conducting early phase clinical trials in children difficult, developments over the past decade 
have addressed many of these issues and have provided the opportunity – indeed, in some 
cases the requirement – for the inclusion of children even in early stage of drug development 
(Figure 1).  While there are new issues – such as the development of drugs for the neonate, 
the increasing appreciation of the importance of drug transporters in drug disposition in 
children and the complex issues raised by the increasing use of biologicals – that pose new 
and interesting challenges for paediatric pharmacy and clinical pharmacology there has never 
been a more promising time for drug development in children (57-60).     
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General overview of the Drug Development Process 
Modified from Council of Canadian Academies: The Expert Panel on Therapeutic Products 
for Infants, Children and Youth.  Improving Medicines for Children in Canada.  Council of 









Considerations in planning the design of an early Phase drug trial in children.  A key aspect 
in planning relates to early decisions as to the need for a flexible design.     
Modified from Council of Canadian Academies: The Expert Panel on Therapeutic Products 
for Infants, Children and Youth.  Improving Medicines for Children in Canada.  Council of 
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Phase of Drug 
Development 
Goal of Studies Examples in Paediatric Drug 
Development 
Phase I First Stages of Drug Testing in 
Humans, typically conducted in 
health adult volunteers 
Very rarely done in children 
with the expectation of 
oncology drug (chemotherapy) 
and some drugs in neonatology 
(surfactant) 
Phase II First Stages of Drug Testing for 
Efficacy and Safety, typically 
conducted in patients 
Uncommon, and represent the 
first step for most drugs in 
terms of early phase studies in 
children. Regulatory advances 
have increased these studies for 
new drugs 
Phase III Effectiveness of the Drug and the 
Role in Clinical Practice, typically 
by comparison with “gold 
standard” therapy 
Done at some times for drugs 
in children, most frequently for 
anti-infectives and increasingly 
for other drug classes 
 
 
Table 1.  Phases of Pre-Clinical Drug Development in Humans and Examples in Paediatrics.   
 
